Webinar:

Respiratory Syncytial Virus Opportunity Analysis and Forecasts to 2028

Sponsored by: GlobalData

Focused on:

  • Respiratory Syncytial Virus
  • Disease Management

Date: 30 July

Days to go: 12

Time: 3PM London/10AM New York

Emerging Prophylactic Agents will Grow the RSV Market by Expanding Patient Pools Eligible for Treatment

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection globally, particularly in infant and elderly populations. Current disease management strategies for RSV are primarily supportive through fluid replacement, administration of supplemental oxygen, and use of bronchodilators in rare occasions for severe disease. As a result, development and commercialization of RSV therapeutics has become a major priority for both large and small pharmaceutical companies.

The burden of RSV-associated illness is well known; however, challenges stemming from both product and clinical trial design have resulted in several high-profile product failures across all classes of agents including antivirals and prophylactic vaccines and antibodies. Further, the RSV market has seen contraction as the only approved prophylactic antibody, AbbVie and AstraZeneca’s Synagis (palivizumab), received an updated recommendation from the American Academy of Pediatrics (AAP) in 2014 for a more narrow population than the antibody is labeled for (i.e., pediatric patients at increased risk of hospitalization due to RSV). These difficulties have limited options for patients currently at risk for complications due to RSV; however, they have driven strong developer interest in addressing RSV across multiple therapeutic avenues.

In this webinar Paul Jeng, Senior Analyst at GlobalData, will present an analysis of the overall RSV pipeline with an emphasis on addressing patient groups of high unmet need, by drawing on insights from GlobalData’s recently published report, Respiratory Syncytial Virus Opportunity Analysis and Forecasts to 2028. An analysis of the currently available Synagis will be provided as well as evaluations of emerging antivirals, vaccines, and prophylactic antibodies. Some of the highest ranking molecular targets will be profiled in detail. Michael Breen, Associate Director at GlobalData, will moderate a Q&A session following the presentation.

Presented by

Paul Jeng, PhD,

Senior Healthcare Analyst

Paul Jeng, PhD is a Senior Infectious Disease Analyst at GlobalData in Boston. Prior to GlobalData, Paul worked as a research fellow at the Memorial Sloan Kettering Cancer Center, where he managed an industry-academic drug discovery collaboration focused on targeting oncoproteins with small molecules for cancer therapy. Paul graduated from Brown University with a BSc with Honors in Biology and Molecular Pharmacology, and received a PhD in Pharmacology from Cornell University where his research focused on dysregulated cell death pathways in cancer. As a doctoral student, Paul was involved in organizing departmental and institutional events, including serving as the chair for student research symposia and on the leadership team of the graduate student biotechnology club. He also has experience with life sciences consulting and freelance science writing.

Michael Breen, PhD,

Associate Director, Infectious Diseases

Michael Breen, PhD, is the Associate Director of Infectious Diseases at GlobalData in Boston. He has over five years of experience in market analysis, business intelligence, and providing strategic insight for the pharmaceutical industry. Prior to his current role, he was a Senior Analyst for Decision Resources Group, where he gained extensive experience writing in-depth reports and developing forecasts for a variety of indications, including rare and infectious diseases and vaccines. Michael has a BA in biology and biochemistry from Hunter College, and a PhD in biochemistry from Boston University School of Medicine.

Key Learning Objectives

  • Learn how GlobalData has assessed the potential impact of therapeutics targeting RSV
  • Gain insight into which prophylactic vaccines and antibodies GlobalData deems to be the most promising for RSV
  • Assess the RSV pipeline by stage of development and type of intervention
  • Learn which companies are most advanced for development of potential RSV-addressing agents

Audience

  • Managers/Senior Managers/Associate Directors/Directors of Market Research
  • Business Insights
  • Market Intelligence
  • Strategic Insights
  • Forecasting
  • Pipeline Management
  • Competitive Strategy
  • Customer Insights
  • Heads of Research and Development
  • Heads of Product Planning and Marketing
  • Brand Managers